ArticleJournal of hepatocellular carcinoma2026
Multi-Target Tyrosine Kinase Inhibitors as Adjuvant Therapy for Hepatocellular Carcinoma Patients Who Achieve Complete Response After Transarterial Chemoembolization: A Real-World Study.
Wei Tang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.